

Appln No.: 10/075,947  
Amendment Dated: April 25, 2004  
Reply to Office Action of March 25, 2004


#### REMARKS/ARGUMENTS

This is in response to the Office Action mailed March 25, 2004 for the above-captioned application. In response to the restriction requirement presented in that paper, Applicants hereby elect the invention of Group 3, as embodied by claim 11 of the original application.

As a first matter, it appears that the Examiner has failed to take into account the Preliminary Amendment filed June 5, 2002 as part of the Response to Notice to Comply. This amendment modified claim 11, and increased the number of claims to 28. Applicants have now submitted a further amendment, which places claim 11 in generic form, converts claim 23 which referred to a single nucleotide sequence (Seq. ID No. 1) to dependent form, and added dependent claims 30-40 to the application to recite Seq. ID No. 2, and the incorporation of therapeutic or pre-therapeutic moieties in the expressed polynucleotide.

It is noted that this preliminary amendment in the Response to Notice to Comply also amended the specification. Applicants request confirmation that these amendments have now been entered.

Respectfully Submitted,



Marina T. Larson, Ph.D  
Attorney/Agent for Applicant(s)  
Reg. No. 32038

(970) 468 6600